The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1607
ISSUE1607
September 21, 2020
Influenza Vaccine for 2020-2021
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Influenza Vaccine for 2020-2021
September 21, 2020 (Issue: 1607)
Annual vaccination against influenza A and B viruses
is recommended for everyone ≥6 months old without a
contraindication. Vaccination of all eligible persons can
reduce the prevalence of influenza illness and symptoms
that might be confused...more
- LA Grohskopf et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices – United States, 2020-21 influenza season. MMWR Recomm Rep 2020; 69:1.
- World Health Organization. Influenza update – 375. Available at: https://bit.ly/3i8IAOB. Accessed September 10, 2020.
- W Schaffner et al. Seasonal influenza immunisation: strategies for older adults. Int J Clin Pract 2018; 72:e13249.
- R Ray et al. A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control. Hum Vaccin Immunother 2017; 13:1640.
- WEP Beyer et al. Rationale for two influenza B lineages in seasonal vaccines: a meta-regression study on immunogenicity and controlled field trials. Vaccine 2017; 35:4167.
- C Arriola et al. Influenza vaccination modifies disease severity among community-dwelling adults hospitalized with influenza. Clin Infect Dis 2017; 65:1289.
- B Flannery et al. Influenza vaccine effectiveness against pediatric deaths: 2010-2014. Pediatrics 2017; 139:e20164244.
- AP Campbell et al. Influenza vaccine effectiveness against laboratory-confirmed influenza in children hospitalized with respiratory illness in the United States, 2016-17 and 2017-18 seasons. Presented at ID Week, Washington, DC, October 2-6, 2019. Abstract 899. Available at: https://bit.ly/35bFoOL. Accessed September 10, 2020.
- S Garg et al. Influenza vaccine reduces risk of severe outcomes among adults hospitalized with influenza A(H1N1)pdm09, FluServ-NET, 2013-2018. Presented at ID Week, Washington, DC, October 2-6, 2019. Abstract 898. Available at: https://bit.ly/3lIEr6e. Accessed September 10, 2020.
- EA Belongia et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis 2016; 16:942.
- M Darvishian et al. Effectiveness of seasonal influenza vaccine in community-dwelling elderly people: a meta-analysis of test-negative design case-control studies. Lancet Infect Dis 2014; 14:1228.
- MA Rolfes et al. Effects of influenza vaccination in the United States during the 2017-2018 influenza season. Clin Infect Dis 2019; 69:1845.
- FS Dawood et al. Interim estimates of 2019-20 seasonal influenza vaccine effectiveness – United States, February 2020. MMWR Morb Mortal Wkly Rep 2020; 69:177.
- J Benjamin-Chung et al. Evaluation of a city-wide school-located influenza vaccination program in Oakland, California, with respect to vaccination coverage, school absences, and laboratory-confirmed influenza: a matched cohort study. Plos Medicine 2020; 17:e1003238.
- Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2020-2021. Pediatrics 2020 September 8 (epub).
- JR Chung et al. Live attenuated and inactivated influenza vaccine effectiveness. Pediatrics 2019; 143:e20182094.
- ML Jackson et al. Influenza vaccine effectiveness in the United States during the 2015-2016 season. N Engl J Med 2017; 377:534.
- SA Buchan et al. Effectiveness of live attenuated vs inactivated influenza vaccines in children during the 2012-2013 through 2015-2016 influenza seasons in Alberta, Canada: a Canadian Immunization Research Network (CIRN) study. JAMA Pediatr 2018; 172:e181514.
- B Young et al. Do antibody responses to the influenza vaccine persist year-round in the elderly? A systematic review and meta-analysis. Vaccine 2017; 35:212.
- JY Song et al. Long-term immunogenicity of influenza vaccine among the elderly: risk factors for poor immune response and persistence. Vaccine 2010; 28:3929.
- ML Anderson et al. The effect of influenza vaccination for the elderly on hospitalization and mortality: an observational study with a regression discontinuity design. Ann Intern Med 2020; 172:445.
- R Baxter et al. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine 2011; 29:2272.
- LM Dunkle et al. Efficacy of recombinant influenza vaccine in adults 50 years of age or older. N Engl J Med 2017; 376:2427.
- EB Chahine. High-dose inactivated influenza vaccine quadrivalent for older adults. Ann Pharmacother 2020 Jun 24 (epub).
- LJ Chang et al. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: a phase 3 randomized clinical trial. Vaccine 2019; 37:5825.
- CA DiazGranados et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med 2014; 371:635.
- S Gravenstein et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US nursing home residents admitted to hospital: a cluster-randomised trial. Lancet Respir Med 2017; 5:738.
- DK Shay et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines among US Medicare beneficiaries in preventing postinfluenza deaths during 2012-2013 and 2013-2014. J Infect Dis 2017; 215:510.
- JKH Lee et al. Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis. Expert Rev Vaccines 2018; 17:435.
- Y Young-Xu et al. High-dose influenza vaccination and mortality among predominantly male, white, senior veterans, United States, 2012/13 to 2014/2015. Vaccine 2020; 25:1900401.
- R van Aalst et al. Comparative effectiveness of high dose versus adjuvanted influenza vaccine: a retrospective cohort study. Vaccine 2020; 38:372.
- Fluad – an adjuvanted seasonal influenza vaccine for older adults. Med Lett Drugs Ther 2016; 58:8.
- SE Frey et al. Comparison of the safety and immunogenicity of an MF59-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine 2014; 32:5027.
- PG Van Buynder et al. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. Vaccine 2013; 31:6122.
- S Mannino et al. Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. Am J Epidemiol 2012; 176:527.
- CDC. Addressing concerns pregnant women might have about influenza vaccine safety. Available at: https://bit.ly/3jDkTyg. Accessed September 10, 2020.
- ACOG Committee Opinion No. 732: influenza vaccination during pregnancy. Obstet Gynecol 2018; 131:e109.
- MG Thompson et al. Effectiveness of seasonal trivalent influenza vaccine for preventing influenza virus illness among pregnant women: a population-based case-control study during the 2010-2011 and 2011-2012 influenza seasons. Clin Infect Dis 2014; 58:449.
- MG Thompson et al. Influenza vaccine effectiveness in preventing influenza-associated hospitalizations during pregnancy: a multi-country retrospective test negative design study, 2010-2016. Clin Infect Dis 2019; 68:1444.
- SG Sullivan et al. Burden, effectiveness and safety of influenza vaccines in elderly, paediatric and pregnant populations. Ther Adv Vaccines Immunother 2019; 7:1.
- M Greenhawt et al. Administration of influenza vaccines to egg allergic recipients: a practice parameter update 2017. Ann Allergy Asthma Immunol 2018; 120:49.
- Y Natori et al. A double-blind, randomized trial of high-dose vs standard-dose influenza vaccine in adult solid-organ transplant recipients. Clin Infect Dis 2018; 66:1698.
- AG L'Huillier et al. Cell-mediated immune responses after influenza vaccination of solid organ transplant recipients: secondary outcomes analyses of a randomized controlled trial. J Infect Dis 2020; 221:53.
- I Colmegna et al. Efficacy of high-dose versus standard-dose influenza vaccine in seropositive rheumatoid arthritis patients. Arthritis Rheumatol 2018; 70 (suppl 10). Abstract 837.
- JC Kwong et al. Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study. Lancet Infect Dis 2013; 13:769.
- LL Polakowski et al. Chart-confirmed Guillain-Barré syndrome after 2009 H1N1 influenza vaccination among the Medicare population, 2009-2010. Am J Epidemiol 2013; 178:962.
- TF Schwarz et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine coadministered with seasonal influenza vaccine in adults aged 50 years or older. J Infect Dis 2017; 216:1352.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Influenza Vaccine for 2020-2021
Article code: 1607a
Article code: 1607a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.